Empowering a Healthier Africa Through Innovation
At JCRC-ABT CellGene Innovations, we bring lifesaving, advanced therapies like stem cell and gene therapy to Africa. Our mission is to empower underserved communities across Africa with innovative medical solutions that save lives.
We Transform Lives, One Breakthrough at a Time
JCRC-ABT CellGene Innovations is dedicated to bridging healthcare gaps with high-quality regenerative treatments. From autoimmune diseases to chronic conditions, we offer cutting-edge therapies tailored to patient needs.
It’s not just about the therapies—it’s about trust, safety, and quality care. Backed by global partnerships and the strictest GMP-certified standards, we are committed to making innovative medicine accessible to all.
Our Treatments
Revolutionizing Care Through Innovation
Conditions We Treat
Personalized Care for Diverse Issues
OUR UNIQUENESS
Why Choose Us?
Personalized,
Patient-Centered Care
Every treatment plan is tailored to your unique needs, goals, and medical history, ensuring a truly personalized approach.
Safe, GMP-Certified
Treatments
Our therapies meet the highest international standards for safety and quality, ensuring every patient receives the best possible care.
Global Expertise with Local
Impact
With strong international partnerships and a deep commitment to Africa, we combine global innovation with a focus on local accessibility.
Advanced Therapies Backed by Research
We leverage the latest advancements in regenerative medicine, including stem cell and gene therapy, developed through collaborations with global leaders in healthcare and biotechnology.
Secure and Streamlined Processes
Every treatment plan is tailored to your unique needs, goals, and medical history, ensuring a truly personalized approach.
Proven Track Record in Transformative Therapies
Our therapies have changed lives, offering new hope to patients facing chronic, degenerative, and life-threatening conditions.
Cutting-Edge Facilities and Technology
Our state-of-the-art labs and advanced medical equipment ensure the highest precision and effectiveness in every treatment we deliver.
Comprehensive Support from Start to Finish
From your initial application to post-treatment follow-ups, our team provides ongoing guidance, support, and resources to ensure your journey is seamless and stress-free.
Our Trusted Partners: Delivering Excellence Together
At JCRC-ABT CellGene Innovations, we are proud to partner with globally renowned suppliers to ensure the highest quality in our therapies. From GMP-certified stem cells to cutting-edge gene therapy solutions, our suppliers adhere to the most rigorous international safety and efficacy standards.
Our primary supplier is based in Europe and specializes in the production of high-quality stem cells under EU-GMP guidelines. With partnerships spanning leading institutions like Karolinska University, they bring decades of research and innovation to every cell we use.
Take The First Step With JCRC-ABT CellGene Innovations
Whether it’s our expert team, compassionate care, or state-of-the-art facilities, you can count on us to be by your side every step of the way
Achievements
Case Studies
Acute Lymphoblastic Leukemia (ALL)
A study in Blood highlighted the success of CAR-T cell therapy (tisagenlecleucel) in pediatric and young adult patients with relapsed/refractory ALL. Over 80% achieved complete remission within one month of treatment, with sustained responses observed in more than 50% at 12 months.
Non-Small Cell Lung Cancer (NSCLC)
Research published in Nature showed that combining nivolumab (anti-PD-1) with ipilimumab (anti-CTLA-4) significantly improved progression-free survival in advanced NSCLC patients. The combination therapy demonstrated a 36% reduction in disease progression risk compared to chemotherapy.
Melanoma
A pivotal study in The New England Journal of Medicine demonstrated the efficacy of immune checkpoint inhibitors like pembrolizumab (anti-PD-1) in advanced melanoma. Patients experienced a 5-year overall survival rate of 43%, with durable tumor regression and manageable side effects, marking a breakthrough in melanoma treatment.
Cystic Fibrosis
A trial targeting CFTR gene mutations delivered via aerosolized vectors showed improved pulmonary function in patients with cystic fibrosis. Published in The Lancet Respiratory Medicine, the therapy reduced hospitalizations and improved quality of life metrics over 12 months.
Hemophilia B
Gene therapy using an AAV vector to deliver the FIX gene resulted in sustained Factor IX production in patients. A landmark study in Blood reported a significant reduction in bleeding episodes and factor replacement therapy use, lasting up to 5 years.
Leber’s Congenital Amaurosis (LCA)
The gene therapy Luxturna restored partial vision in patients with RPE65 gene mutations. Clinical trials demonstrated improved light sensitivity and navigation abilities, with effects persisting for over three years.
Your Ultimate Guide to Stem Cell Therapy: Insights from JCRC-ABT Experts
Discover the transformative potential of cutting-edge stem cell therapy with JCRC-ABT CellGene Innovations. This guide offers a deep dive into our pioneering “Golden Cells” technology, treatment processes, and the conditions we treat—from chronic illnesses to neurological disorders. Learn about the science, benefits, and the patient experience in Kampala, Uganda.
